Jean-Christophe Renondin - 09 Aug 2023 Form 3 Insider Report for AgeX Therapeutics, Inc. (SER)

Role
Director
Signature
/s/Jean-Christophe Renondin
Issuer symbol
SER
Transactions as of
09 Aug 2023
Net transactions value
$0
Form type
3
Filing time
21 Aug 2023, 16:40:43 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AGE Option to Purchase Common Stock 09 Aug 2023 Common Stock 25,821 $0.7600 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock options will vest in quarterly installments based upon Dr. Renondin's continued service as a director, with options to purchase 9,571 scheduled to vest on September 30, 2023 and options to purchase 16,250 shares scheduled to vest on December 31, 2023.